英菲格拉替尼疗效怎么样,有副作用吗?

Infigratinib is an innovative, oral, ATP-competitive FGFR1-3 tyrosine kinase inhibitor that blocks downstream signaling cascades by selectively binding and inhibiting FGFR activity, reducing cancer cell proliferation and inducing tumor cell death. It was approved for marketing by the US FDA on May 21, 2021. So, what is the efficacy and are there any side effects?

How effective is Infigratinib?

A phase 2 trial (NCT02150967) showed a blinded independent central review (BICR)-assessed objective response rate (ORR) of 23.1% for infilatinib at a median follow-up of 10.6 months (range, 6.2-15.6). These findings included 1 complete response (CR; 1%) and 24 partial responses (PR; 22%). A multi-center, single-group clinical study included 71 subjects. The results showed that in the case of second-line treatment, the median progression-free survival (PFS) of patients was 4.63 months; the median PFS of patients receiving third-line and above treatment with infigratinib was 6.77 months. In other words, infigratinib can prolong the survival period of patients and improve their quality of life.

Does Infigratinib have any side effects?

Infigratinib has side effects, including nail toxicity, constipation, abdominal pain, dry mouth, stomatitis, dry eye, fatigue, alopecia, palmoplantar erythema syndrome, joint pain, dysgeusia, dry skin, loss of appetite, eyelash changes, diarrhea, blurred vision, vomiting, etc. Patients should pay attention to their own reactions during medication. If they are intolerant, contact their doctor promptly for symptomatic treatment.

Infigratinib has high affinity for FGFR 1, 2 and 3 and is an oral FGFR selective inhibitor. It was originally developed by Novartis and has shown good efficacy in many clinical trials. The above is about the efficacy of Infigratinib and whether it has any side effects. I hope it can help you!

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: